section name header

Pronunciation

vor-IN-o-stat

Classifications

Therapeutic Classification: antineoplastics

Pharmacologic Classification: enzyme inhibitors

Indications

High Alert


Action

  • Acts as a histone deacetylase inhibitor, which decreases gene transcription resulting in cell cycle arrest.
Therapeutic effects:
  • Decreased progression of cutaneous T-cell lymphoma.

Pharmacokinetics

Absorption: Well absorbed following oral administration.

Distribution: Unknown.

Metabolism/Excretion: Mostly metabolized, <1% excreted unchanged in urine.

Half-Life: 2 hr.

Time/Action Profile

(plasma concentrations)

ROUTEONSETPEAKDURATION
POunknown4 hr24 hr





Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

CV: DEEP VEIN THROMBOSIS, QT interval prolongation

Derm: alopecia, itching

Endo: hyperglycemia

GI: anorexia, constipation, diarrhea, dry mouth, nausea, vomiting

GU: fertility (women), proteinuria

Hemat: anemia, thrombocytopenia

Metab: weight loss

MS: muscle spasms

Neuro: dysgeusia, dizziness, headache

Resp: cough, PULMONARY EMBOLISM

Misc: chills, fever

Interactions

Drug-drug:

Route/Dosage

Availability

Assessment

Lab Test Considerations:

Implementation

Patient/Family Teaching

Evaluation/Desired Outcomes

US Brand Names

Zolinza